Isturisa FDA Approval History
Last updated by Judith Stewart, BPharm on April 22, 2025.
FDA Approved: Yes (First approved March 6, 2020)
Brand name: Isturisa
Generic name: osilodrostat
Dosage form: Tablets
Company: Recordati
Treatment for: Cushing's Syndrome
Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Development timeline for Isturisa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.